Glenmark Pharma bags USFDA nod for Calcipotriene and Betamethasone Dipropionate Foam
The product is a generic version of Enstilar Foam, 0.005%|0.064%, of Leo Pharma AS.
Mumbai: Glenmark Pharmaceuticals Ltd., a global pharmaceuticals company has received final approval from the United States Food & Drug Administration (U.S. FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%.
The drug is an analogue and synthetic corticosteroid fixed-dose combination foam formulation, which is used for the topical treatment of plaque psoriasis in adults.
The product is a generic version of Enstilar Foam, 0.005%|0.064%, of Leo Pharma AS.
"With respect to 180-day generic drug exclusivity, the FDA noted that Glenmark was the first Abbreviated New Drug Application (ANDA) applicant to submit a substantially complete ANDA with a paragraph IV certification for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%. Therefore, with this approval, Glenmark is eligible for 180-days of generic drug exclusivity for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%," the company stated in a release.
Read also: Glenmark Gets CDSCO panel nod for Phase IV CT of Fosnetupitant, Palanosetron FDC drug
According to IQVIA sales data for the 12-month period ending January 2023, the Enstilar Foam, 0.005%|0.064% market achieved annual sales of approximately $93.6 million*.
Glenmark’s current portfolio consists of 183 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA.
Read also: Glenmark Pharma gets final USFDA nod for Schizophrenia drug Prochlorperazine Maleate
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.